C4X Discovery Holdings is set to receive a $13 million milestone payment from AstraZeneca after an oral NRF2 activator program entered the clinic. The trigger reflects AstraZeneca’s continued focus on oxidative stress and inflammation biology through small-molecule NRF2 pathway modulation. The milestone adds to the financing and development cadence for C4X Discovery, which now moves further from discovery toward clinical validation of an oral NRF2 approach. For the broader sector, the payment also signals that NRF2 programs remain active in big-pharma pipelines despite a historically mixed track record for translating antioxidant pathway biology into outcomes. Next steps will focus on early clinical data—dose, tolerability, and target engagement—since these will shape whether the program can advance in competitive cardiovascular, metabolic, or fibrotic disease areas where NRF2 has been tested.